Insider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Acquires 7,000 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction dated Monday, March 24th. The shares were bought at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the acquisition, the director now owns 23,615 shares in the company, valued at $193,879.15. The trade was a 42.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Immunome Price Performance

IMNM stock traded down $1.20 on Tuesday, reaching $6.95. 1,747,431 shares of the company were exchanged, compared to its average volume of 827,029. The firm has a market capitalization of $604.31 million, a PE ratio of -0.86 and a beta of 1.93. Immunome, Inc. has a 12 month low of $8.12 and a 12 month high of $26.70. The stock’s fifty day moving average price is $9.72 and its 200 day moving average price is $11.49.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. As a group, research analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunome

Several large investors have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new stake in shares of Immunome during the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS bought a new position in Immunome in the fourth quarter worth $75,000. AlphaQuest LLC boosted its stake in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after buying an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Immunome during the 4th quarter valued at about $95,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Guggenheim lowered their price target on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Lifesci Capital began coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Stephens restated an “overweight” rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.